MAX BioPharma, Inc. recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells. Oxy186 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562610/) and Oxy210 (https://www.mdpi.com/2073-4409/8/10/1297/pdf) are derived from the Company’s Oxysterol Therapeutics® platform of proprietary oxysterols. MAX BioPharma is currently optimizing the compounds for oral dosing and performing pre-clinical studies required by the FDA for clinical development and commercialization.
MAX BioPharma’s anti-tumorigenic oxysterol….